Navigation Links
ULURU Inc. to Present at the Thomas Weisel Partners Healthcare Conference 2008
Date:9/4/2008

ADDISON, Texas, Sept. 4 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that it is scheduled to present at the Thomas Weisel Partners Healthcare Conference at 3:15 p.m. Eastern Time on Thursday, September 4, 2008.

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the response to the product from physicians and nurses, the importance of use of the product for burn victims, our expectation of enhanced patient comfort, the ability to use the product for chronic wounds, the perception of the product as a transformational innovation in the wound care market, our plan to add two products to our wound care franchise in 2009, and our expectation of filing a 510k in the third quarter and a product launch in the first quarter of 2009. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company

Kerry P. Gray

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
2. ULURU Inc. Reports First Quarter 2008 Financial Results
3. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
8. ULURU Inc. Reports Third Quarter 2007 Results
9. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
10. ULURU Inc. Announces Odd-Lot Buy Back Offer
11. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... are higher than generally thought, raising concerns about increased risk for ... California, San Francisco (UCSF) imaging specialists. , ... ... common CT procedures vary widely and are higher than generally thought, ... study led by University of California, San Francisco (UCSF) ...
(Date:12/14/2009)... Tide of Tens of Thousands of New Chronic ... Legislation approved by Congress providing for ... in helping to reduce tens of thousands of ... the United States, the National Viral Hepatitis ... was included in the FY 2010 Consolidated Appropriations ...
(Date:12/14/2009)... 2009, the United States Court of Appeals, Tenth Circuit, ... are "plans" and therefore subject to federal jurisdiction. (US ... that contracts issued by insurance companies may be subject ... US vs. Frost is the first case an ... "plan," because, as the government claimed in this case, ...
(Date:12/14/2009)... linked to scans performed in 2007 , , MONDAY, Dec. ... patients to far more radiation than previously thought and in ... year, two new studies claim. , Based on the findings, ... of Internal Medicine , the study authors, joined by ... clinicians to limit radiation exposure to patients. , "CT has ...
(Date:12/14/2009)... of scientists from the UC San Diego School of ... protein switch that helps prevent liver damage, including inflammation, ... understanding of how the protein, TAK1, works could lead ... and cancer. , "TAK1 appears to be a ... MD, professor of medicine and Dean of the UC ...
Breaking Medicine News(10 mins):Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Scientists uncover protective mechanism against liver cancer 2
... characterization of renal transplant patients being weaned ... ... Data developed by Cylex in,conjunction with the University of Pittsburgh ... Canada, suggest,that cell-mediated immunity and anti-HLA antibody assays may be independent,measures ...
... For the past 70 years the treatment of ... therapy. That is, the suppression of circulating testosterone ... castration (orchiectomy) or medical castration with testosterone-blocking drugs. While ... a cure, as inevitably the cancer becomes resistant to ...
... time with pancreatic, kidney cancers, respectively , , ... with pancreatic cancer -- which historically carries a ... when the cancer drug Gemzar was used after ... 15 percent of pancreatic cancer patients are even ...
... progression-free survival, study finds , , SATURDAY, May 31 ... chemotherapy lengthened progression-free survival in women with advanced ... have found that adding Avastin (bevacizumab) to the ... breast cancer actually doubled progression-free survival. , Avastin ...
... likely to have diminished ovarian reserve producing viable ... News) -- Chemotherapy may reduce fertility in breast ... researchers at Boston,s Dana-Farber Cancer Institute. , They ... chemotherapy following surgery were more likely than women ...
... and cold medication use in young children has been ... several deaths, leading the FDA to recommend against their ... these concerns about safety and efficacy, there has been ... use in very young children. Now, a new study ...
Other Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3Health News:Chemo May Limit Fertility in Breast Cancer Survivors 2Health News:Study examines cold medication use in young children 2
(Date:12/14/2009)... 14 The 2009 Frost & Sullivan ... Market is conferred on SonoScape. The award recipient ... need for special features, pricing, and portability - ... The performance of this high-end colour Doppler HCU ... echo ultrasound system. ,, (Logo: ...
(Date:12/14/2009)... -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) ... of Allowance from the United States Patent and ... application no. 11/060,641, which covers the composition and ... tablet), the lead Transcept product candidate. Once ... February 2025. ,, "This is the second USPTO ...
(Date:12/14/2009)... Dec. 14 BioTrends Research Group, Inc. ... a syndicated publication offering comprehensive insight into the ... based on a comparison of self-reported treatment approaches ... level data for over 1,000 RA patients who ... To be eligible for the audit, patients had ...
Breaking Medicine Technology:Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8 2Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8 3Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 2Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 3Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 4New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 2New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 3NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd and U S Institutional and Private Investors Bringing the 12865 1NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd and U S Institutional and Private Investors Bringing the 12865 2NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd and U S Institutional and Private Investors Bringing the 12865 3eDiets com 28R 29 Announces Meal Delivery Marketing Partnership With Golds Gym Franchise Network 50497 1eDiets com 28R 29 Announces Meal Delivery Marketing Partnership With Golds Gym Franchise Network 50497 2eDiets com 28R 29 Announces Meal Delivery Marketing Partnership With Golds Gym Franchise Network 50497 3Calling All Runners 3A Join the Fight Against Cancer 50493 1Calling All Runners 3A Join the Fight Against Cancer 50493 2
Round knurled handle. Overall length 130 mm....
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
DIX foreign body spud 4 3/4 inches, 1.7 x 15 mm blade....
Foreign body spud very thin, lightly curved and rounded tip....
Medicine Products: